tesa+ipa blend
Tesamorelin plus ipamorelin combines two growth-hormone secretagogues. Tesamorelin has an approved use for excess abdominal fat in adults with HIV-associated lipodystrophy. That approval does not cover adding ipamorelin or treating general weight gain.
GHRH analog + ghrelin-receptor agonist
- GHRH analog + ghrelin-receptor agonist
- Egrifta evidence belongs to tesamorelin alone
Is this the same treatment as Egrifta?
No. Egrifta is a specified tesamorelin product. A tesamorelin/ipamorelin mixture has another active ingredient and may use a different preparation. Egrifta’s indication, instructions and trial results cannot be assigned to it.
Egrifta WR · indication and risks
FDA prescribing information
Egrifta WR (tesamorelin), US prescribing information, revised March 2025.
Egrifta WR is indicated for excess abdominal fat in adults with HIV-associated lipodystrophy, not general weight management. The March 2025 label lists pituitary-axis disruption, active malignancy, pregnancy and hypersensitivity as contraindications. Warnings include elevated IGF-1, fluid retention, glucose intolerance and hypersensitivity. These are tesamorelin product findings, not a characterized safety profile for a blend.
Read the original sourceHas this exact combination been tested?
The cited PubMed records contain no controlled outcome study of the tesamorelin/ipamorelin finished combination. The clinical benefit for tesamorelin belongs to its own product and studied population.
Evidence for the exact combination
Combination evidence
PubMed.
No controlled outcome study has tested the finished tesamorelin/ipamorelin combination. Tesamorelin's clinical benefit belongs to its own product and studied population.
Does adding ipamorelin improve fat loss, sleep or recovery?
No controlled clinical trial shows that adding ipamorelin improves fat loss, sleep, or recovery. Receptor pharmacology alone cannot establish those outcomes.
What about the evidence for abdominal fat?
Egrifta WR’s label concerns excess abdominal fat in adults with HIV-associated lipodystrophy. It specifically excludes general weight management. It does not test adding ipamorelin to improve that result.
Evidence for the exact combination
Combination evidence
PubMed.
No controlled outcome study has tested the finished tesamorelin/ipamorelin combination. Tesamorelin's clinical benefit belongs to its own product and studied population.
Why are the two ingredients paired?
Tesamorelin stimulates the GHRH side of growth-hormone release. Ipamorelin targets a different receptor involved in GH secretion. A response to two inputs does not establish a predictable improvement over prescribed tesamorelin in the condition being treated.
Egrifta WR · indication and risks
FDA prescribing information
Egrifta WR (tesamorelin), US prescribing information, revised March 2025.
Egrifta WR is indicated for excess abdominal fat in adults with HIV-associated lipodystrophy, not general weight management. The March 2025 label lists pituitary-axis disruption, active malignancy, pregnancy and hypersensitivity as contraindications. Warnings include elevated IGF-1, fluid retention, glucose intolerance and hypersensitivity. These are tesamorelin product findings, not a characterized safety profile for a blend.
Read the original sourceFDA · ingredient safety concerns
Regulatory safety assessment
FDA · ingredient safety concerns
FDA identifies incomplete human safety data and peptide impurity or immune-reaction concerns for ipamorelin. Serious events, including deaths, occurred in an intravenous study, but the record does not establish causation or the risk of other routes.
Read the original sourceWhat risks are known?
Tesamorelin’s label warns about elevated IGF-1, fluid retention, glucose intolerance and hypersensitivity. Ipamorelin has unresolved route-specific safety questions, and the combination has no measured safety profile.
Who cannot use the approved tesamorelin product?
The Egrifta WR label lists active malignancy, disruption of the hypothalamic-pituitary axis, pregnancy and known hypersensitivity among its contraindications. Those restrictions remain relevant to a tesamorelin-containing proposal; they do not form a complete safety assessment for the blend.
What about other medicines?
The label addresses possible interactions with CYP450-metabolized medicines and glucocorticoid replacement. Adding another GH secretagogue has not been shown to remove the need for medication and endocrine review.
Egrifta WR · indication and risks
FDA prescribing information
Egrifta WR (tesamorelin), US prescribing information, revised March 2025.
Egrifta WR is indicated for excess abdominal fat in adults with HIV-associated lipodystrophy, not general weight management. The March 2025 label lists pituitary-axis disruption, active malignancy, pregnancy and hypersensitivity as contraindications. Warnings include elevated IGF-1, fluid retention, glucose intolerance and hypersensitivity. These are tesamorelin product findings, not a characterized safety profile for a blend.
Read the original sourceFDA · ingredient safety concerns
Regulatory safety assessment
FDA · ingredient safety concerns
FDA identifies incomplete human safety data and peptide impurity or immune-reaction concerns for ipamorelin. Serious events, including deaths, occurred in an intravenous study, but the record does not establish causation or the risk of other routes.
Read the original sourceCan I use Egrifta’s mixing and storage instructions?
No. Even Egrifta WR and Egrifta SV have different preparation requirements and are not substitutable. Those product-specific instructions do not validate mixing tesamorelin with ipamorelin or using a research-vial formulation.
Egrifta WR · indication and risks
FDA prescribing information
Egrifta WR (tesamorelin), US prescribing information, revised March 2025.
Egrifta WR is indicated for excess abdominal fat in adults with HIV-associated lipodystrophy, not general weight management. The March 2025 label lists pituitary-axis disruption, active malignancy, pregnancy and hypersensitivity as contraindications. Warnings include elevated IGF-1, fluid retention, glucose intolerance and hypersensitivity. These are tesamorelin product findings, not a characterized safety profile for a blend.
Read the original sourceStudies and sources
Egrifta WR · indication and risks
FDA prescribing information
Egrifta WR (tesamorelin), US prescribing information, revised March 2025.
Egrifta WR is indicated for excess abdominal fat in adults with HIV-associated lipodystrophy, not general weight management. The March 2025 label lists pituitary-axis disruption, active malignancy, pregnancy and hypersensitivity as contraindications. Warnings include elevated IGF-1, fluid retention, glucose intolerance and hypersensitivity. These are tesamorelin product findings, not a characterized safety profile for a blend.
Read the original sourceFDA · ingredient safety concerns
Regulatory safety assessment
FDA · ingredient safety concerns
FDA identifies incomplete human safety data and peptide impurity or immune-reaction concerns for ipamorelin. Serious events, including deaths, occurred in an intravenous study, but the record does not establish causation or the risk of other routes.
Read the original sourceEvidence for the exact combination
Combination evidence
PubMed.
No controlled outcome study has tested the finished tesamorelin/ipamorelin combination. Tesamorelin's clinical benefit belongs to its own product and studied population.
Why is tesa+ipa blend in A tier?
The A grade rests on tesamorelin evidence in HIV-associated lipodystrophy. No controlled trial shows that adding ipamorelin improves benefit or preserves the approved product's safety profile.